Effects of Ipragliflozin on Body Composition in Type 1 Diabetic Patients

Effects of Ipragliflozin on Body Composition in Type 1 Diabetic Patients - Effects of Ipragliflozin on Body Composition in Type 1 Diabetic Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036039

Enrollment

Registered

2019-03-01

Start date

2019-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 1 diabetic patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Out patients who receive therapy at our hospital Type 1 diabetic patients HbA1c: >= 7.0 and < 10% Patients who give written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients who had ketoacidosis or coma Malignancies or other diseases with poor prognosis eGFR<60mL/min/1.73m2

Design outcomes

Primary

Measure	Time frame
Body Composition	—

Countries

Japan

Contacts

Public Contactsatoshi ida

Ise Red Cross Hospital Department of diabetes and metabolism

bboy98762006@yahoo.co.jp0596-28-2171

Outcome results